Abstract:Opinion statementWith advances in treatments and survival of patients with glioblastoma (GBM), it has become apparent that conventional imaging sequences have significant limitations both in terms of assessing response to treatment and monitoring disease progression. Both ‘pseudoprogression’ after chemoradiation for newly diagnosed GBM and ‘pseudoresponse’ after anti-angiogenesis treatment for relapsed GBM are well-recognised radiological entities. This in turn has led to revision of response criteria away from the standard MacDonald criteria, which depend on the two-dimensional measurement of contrast-enhancing tumour, and which have been the primary measure of radiological response for over three decades. A working party of experts published RANO (Response Assessment in Neuro-oncology Working Group) criteria in 2010 which take into account signal change on T2/FLAIR sequences as well as the contrast-enhancing component of the tumour. These have recently been modified for immune therapies, which are associated with specific issues related to the timing of radiological response. There has been increasing interest in quantification and validation of physiological and metabolic parameters in GBM over the last 10 years utilising the wide range of advanced imaging techniques available on standard MRI platforms. Previously, MRI would provide structural information only on the anatomical location of the tumour and the presence or absence of a disrupted blood-brain barrier. Advanced MRI sequences include proton magnetic resonance spectroscopy (MRS), vascular imaging (perfusion/permeability) and diffusion imaging (diffusion weighted imaging/diffusion tensor imaging) and are now routinely available. They provide biologically relevant functional, haemodynamic, cellular, metabolic and cytoarchitectural information and are being evaluated in clinical trials to determine whether they offer superior biomarkers of early treatment response than conventional imaging, when correlated with hard survival endpoints. Multiparametric imaging, incorporating different combinations of these modalities, improves accuracy over single imaging modalities but has not been widely adopted due to the amount of post-processing analysis required, lack of clinical trial data, lack of radiology training and wide variations in threshold values. New techniques including diffusion kurtosis and radiomics will offer a higher level of quantification but will require validation in clinical trial settings. Given all these considerations, it is clear that there is an urgent need to incorporate advanced techniques into clinical trial design to avoid the problems of under or over assessment of treatment response.

Intérêt Des Séquences Avancées En IRM Dans L’évaluation À La Réponse Au Bevacizumab. Suivi Multimodal De 20 Glioblastomes

Importance Des Variations Spectrales Durant 36 Mois De Suivi Longitudinal IRM Et SRM De 80 Patients Atteints De Glioblastomes Traités

Suivi Longitudinal IRM Et SRM Proton De Patients Attients De Tumeur Gliale Traitee Par Temodal

Suivi Longitudinal IRM Et SRM 1H De 15 Patients Atteints De Tumeur Oligodendrogliale Ou De Gliomatose Sous Temodal

PL02.3.A Survival and T-cell tumor reactivity in patients treated with nivolumab and bevacizumab for recurrent glioblastoma in the clinical trial CA209-9UP

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

Five-Year Longitudinal MRI Follow-up and (1)H Single Voxel MRS in 14 Patients with Gliomatosis Treated with Temodal, Radiotherapy and Antiangiogenic Therapy.

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients

Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab

Advanced MRI Techniques in the Monitoring of Treatment of Gliomas

Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment

Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation

Imaging acute effects of bevacizumab on tumor vascular kinetics in a preclinical orthotopic model of U251 glioma

Un cas de pseudo-progression après RIV par Lu177-DOTATATE d’une tumeur neuroendocrine du grêle métastatique

Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG/RTOG 0825)

Nimg-72. Voxel-Wise, Multivariable, Cox Proportional Hazard Statistical Parameter Mapping To Investigate The Interplay Between Tumor Location, Prognostic Variables, And Experimental Treatment In A Phase 3 Trial Of Newly-Diagnosed Glioblastoma Treated With Chemoradiation With Or Without Bevacizumab